Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued
Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...
Takeda signals 2025 growth with raised guidance, JPY 100B buyback, and new leadership transition
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025Management ViewChristophe Weber, CEO, announced his retirement ...